Background: Stat3, Socs3 and cytokines play an integral role in the coordination and persistence of inflammation. However, a clear understanding of the role played by the Stat3/IL-6 and Socs3 pathway in airway inflammation is lacking. We report the alteration in the status of expression and activation of Stat3 by ovalbumin (OVA), and establish its relationship with Socs3 and IL-6 in the lungs of mice with eosinophilic pulmonary inflammation and airway hyperresponsiveness. Methods: Alterations in the expression of Stat3, Socs3 and IL-6 were determined in a murine model of asthma, where Balb/c mice were sensitized and challenged with OVA (OVA/OVA) and compared with control mice sensitized and challenged with saline (SAL) (SAL/SAL) mice. The OVA/OVA mice were characterized by a moderate increase in methacholine-induced specific airway resistance, the presence of 150 μg/ml of OVA-specific IgG and 8.93 μg/ml OVA-specific IgE antibody and elevated levels of eosinophils and Th2 cytokines (IL-4 and IL-5) in the bronchoalveolar lavage fluid. In contrast SAL/SAL mice had low eosinophils, IL-4 and IL-5 and no OVA-specific IgG and IgE antibodies in the BALF. Stat3 and Socs3 expression profiles were monitored in OVA/OVA and Stat3- and Socs3-silenced OVA/OVA mice. Furthermore, expression of IL-6 in Stat3- and Socs3-silenced mice and the exogenous effect of IL-6 on Stat3 were studied. Results: The results show that expression and activation of Stat3 mRNA and proteins are significantly low in lung of OVA/OVA mice in comparison to SAL/SAL mice following OVA challenge. An increased pool of Socs3 mRNA is observed in OVA/OVA mice with or without OVA challenge and in SAL/SAL mice 24 h after OVA challenge. Transient in vivo blocking of Socs3 gene by Socs3 siRNA restores the expression of IL-6 mRNA and protein in OVA/OVA mice, and nasal administration of recombinant IL-6 to OVA/OVA mice enhanced Stat3 mRNA expression. Conclusions: Our data suggest that airway inflammation is associated with low expression of Stat3 and IL-6 and overexpression of Socs3 genes in a mouse model of asthma. Furthermore, IL-6 is under the influence of the Socs3 gene and may contribute to the negative regulation of Stat3 via IL-6 following a challenge with an allergen during the development of asthma.

1.
Darnell JE: STATs and gene regulation. Science 1997;277:1630–1635.
2.
Seder R, Paul W: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635–673.
3.
Ennis DP, Cassidy JP, Mahon BP: Prior Bordetella pertussis infection modulates allergen priming and severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 2004;34:1488–1497.
4.
Pernis AB, Rothman PB: JAK-STAT signaling in asthma. J Clin Invest 2002;109:1279–1283.
5.
Kuperman D, Schofield B, Wills-Karp M, Grusby MJ: Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998;187:939–948.
6.
Akimoto T, Numata F, Tamura M, et al: Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 1998;187:1537–1542.
7.
Miyata S, Matsuyama T, Kodama T, et al: STAT6 deficiency in a mouse model of allergen-induced abolishes eosinophilia but induces infiltration of CD8+ T cells. Clin Exp Allergy 1999;29:114–123.
8.
Herrick CA, MacLeod H, Glusac E, Tigelaar RE, Bottomly K: Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J Clin Invest 2000;105:765–775.
9.
Tomkinson A, Kanehiro A, Rabinovitch N, Joetham A, Cieslewicz G, Gelfand EW: The failure of STAT6-deficient mice to develop eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 1999;160:1283–1291.
10.
Miller RL, Eppinger TM, McConnell D, Cunningham-Rundles C, Rothman P: Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E. J Allergy Clin Immunol 1998;102:503–511.
11.
Christodoulopoulos P, Cameron L, Nakamura Y, et al: Th2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol 2001;107:586–591.
12.
Mullings RE, Wilson SJ, Puddicombe SM, et al: Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. J Allergy Clin Immunol 2001;108:832–838.
13.
Zhong Z, Wen Z, Darnell JE Jr: Stat3: a Stat family member activated by tyrosine phosphorylation in response to epidermal growth factor and IL-6. Science 1994;264:95–98.
14.
Darnell JE Jr: Stat and gene regulation. Science 1997;277:1630–1635.
15.
Leonard WJ, O’Shea JJ: Jaks and Stats: biological implications. Annu Rev Immun 1998;16:293–322.
16.
Akira S: IL-6 regulated transcription factors. Int J Biochem Cell Biol 1997;29:1401–1418.
17.
Bromberg J, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468–2473.
18.
Cheng F, Wang H, Cuena A, Huang M, Ghansah T, Brayer J, Kerr W, Takeda K, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E: A critical role for Stat3 signaling in immune tolerance. Immunity 2003;19:425–436.
19.
Alonzi T, Maritano D, Gorgoni B, Rizzuto G, Libert C, Poli V: Essential role of Stat 3 in the control of the acute phase response as revealed by inducible gene inactivation in the liver. Mol Cell Biol 2001;21:1621–1632.
20.
Andrejko KM, Chen J, Deutschman CS: Intrahepatic Stat3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat. Am J Physiol 1998;275:1423–1429.
21.
Hanada T, Yoshida T, Kinjyo I, Minoguchi S, Yasukawa H, Kato S, Mimata H, Nomura Y, Seki Y, Kubo M, Yoshimura AA: Mutant form of JAB/SOCS1 augments the cytokine induced JAK/STAT pathway by accelerating degradation of wild type JAB/CIS family proteins through the SOCS-box. J Biol Chem 2001;276:40746–40754.
22.
Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39–49.
23.
Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamota Y, Li E, Craft JE, Bothwell AL, Fikriq E, Koni PA, Flavell RA, Fu XY: Stat3 deletion during hematopoiesis causes Crohn’s disease like pathogenesis and lethality: A critical role of Stat3 in innate immunity. Proc Natl Acad Sci USA 2003;100:1879–1884.
24.
Gao H, Guo RF, Speyer CL, Reuben J, Neff TA, Hoesel LM, Riedemann NC, McClintock SD, Sarma JV, Rooijen NV, Zetoune FS, Ward PA: Stat3 activation in acute lung injury. J Immunol 2004;172:7703–7712.
25.
Cazes E, Giron-Michel J, Baouz S, Doucet C, Cagnoni F, Oddera S, Korner M, Dasic G, Testi R, Azzarone B, Canonica GW: Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. J Immunol 2001;167:5329–5337.
26.
Tantisira KG, Lake S, Silverman ES, Palmer IJ, Lazarus R, Silverman EK, Liggett SB, Gelfand EW, Richter B, Israel E, Gabriel S, Altshuler D, Lander E, Drazen J, Weiss ST: Corticosteroid pharmacogenetics: Association of sequence variants in CRHRI with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004;13:1353–1359.
27.
Litonjua AA, Tantisira KG, Lake S, Lazarus R, Richter BG, Silverman ES, Weiss TT: Polymorphisms in signal transducer and activator of transcription 3 and lung function in asthma. Respir Res 2005;6:52–61.
28.
Flandre TD, Pascal LL, Daniel J, Desmecht M: Effect of somatic growth, strain, and sex on double chamber plethysmographic respiratory function values in healthy mice. J Appl Physiol 2003;94:1129–1136.
29.
Pennock BE, Cox CP, Rogers RM, Cain A, Wells J: Non-invasive technique for measurement of changes in specific airway resistance. J Appl Physiol 1979;46:399–406.
30.
Sureshkumar V, Paul BN, Uthirappan M, Pandey R, Sahu AP, Lal K, Prasad AP, Srivastava S, Saxena A, Mathur N, Gupta YK: Proinflammatory and anti-inflammatory cytokine balance in gasoline exhaust induced pulmonary injury in mice. Inhal Toxicol 2005;17:161–168.
31.
Geba GP, Wegner CD, Wolyniec WW, Li Y, Askenase PN: Non-atopic asthma: in vitro airway hyperreactivity adoptively transferred to naïve mice by THY-1+ and B220+ antigen- specific cells that lack surface expression of CD3. J Clin Invest 1997;100:629–638.
32.
Vinkemeier U: Getting the message across Stat! Design principles of molecular signaling circuit. J Cell Biol 2004;167:197–201.
33.
Ehlting C, Haussinger D, Bode JG: Sp3 is involved in the regulation of Socs 3 gene expression. Biochem J 2005;387:737–745.
34.
Auernhammer C, Bousquet J, Melmed S: Autoregulation of pituitary coticotroph Socs3 expression: characterization of the murine Socs3 promoter. Proc Natl Acad Sci USA1999;96:6964–6969.
35.
Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T: Structure and function of a new Stat induced Stat inhibitor. Nature 1997;387:924–929.
36.
Davey HW, McLachlan MJ, Wilkins RJ, Hilton DJ, Adams TE: Stat 5b mediates the GH-induced expression of Socs2 and Socs3 mRNA in the liver. Mol Cell Endocrinol 1999;158:111–116.
37.
Alexander WS, Hilton DJ: Role of Socs proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503–529.
38.
Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997;94:3801–3804.
39.
Levy DE, Lee CK: What does Stat3 do? J Clin Invest 2002;109:1143–1148.
40.
Wormald S, Hilton DJ: Inhibitors of cytokine signal transduction. J Biol Chem 2004;279:821–824.
41.
Wormald S, Zhang JG, Krebs DL, Mielke LA, Silver J, Alexander WS, Speed TP, Nicola NA, Hilton DJ: The comparative roles of Socs-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem2006;281:11135–11143.
42.
Gao H, Marco-Hoesel LR, Guo RF, Rancilio NJ, VidyaSarm J, Ward PA: Adenoviral-mediated overexpression of Socs3 enhances IgG immune complex-induced acute lung injury. J Immunol 2006;177:612–620.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.